News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Zynex (ZYXI.OB) Announces Second Quarter 2012 Financial Results



8/8/2012 9:51:25 AM

LONE TREE, CO--(Marketwire - August 07, 2012) -

Zynex, Inc. (OTCBB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announces its second quarter 2012 unaudited financial results.

The Company's total net revenue increased 19% to $10,026,000 for the three months ended June 30, 2012 from $8,395,000 for the three months ended June 30, 2011. Year to date net revenue of $18,970,000 increased 26% over the prior year to date net revenue. The Company's revenue increase for the second quarter and year to date 2012 was primarily driven by its Zynex Medical subsidiary, in which strong demand continues from its products, and a small amount of revenue was derived from its Zynex NeuroDiagnostics subsidiary. The Company generated net income of $473,000, or $0.02 per share in the second quarter of 2012 and net income of $793,000, or $0.03 per share for the first six months of 2012, versus a net income of $484,000, or $0.02 per share in the second quarter of 2011 and net income of $374,000, or $0.01 per share for the first six months of 2011.

The Company reported a gross profit of $8,240,000, or 82% of net revenue, for the second quarter of 2012, and $15,371,000, or 81% of net revenue, for the first six months of 2012, as compared to a gross profit of $6,668,000, or 79% of net revenue, for the second quarter of 2011 and $11,857,000, or 79% of net revenue, for the first six months of 2011.

The Company reported Selling, General and Administrative (SG&A) expenses of $7,308,000, or 73% of net revenue, for the three months ended June 30, 2012, and $13,953,000, or 74% of net revenue, for the six months ended June 30, 2012, as compared to $5,769,000, or 69% of net revenue, for the three months ended June 30, 2011 and $11,097,000, or 74% of net revenue for the six months ended June 30, 2011. Increases in the Company's SG&A expenses during the first three and six months of 2012 were primarily attributable to sales and marketing, specifically for sales commissions (based on the 19% and 26% increase in net revenue) and investments made to expand the Company's Zynex Medical field sales force.

The Company generated a second quarter 2012 income from operations of $932,000, income before income taxes of $844,000 and net income of $473,000, or $0.02 per share, versus a second quarter of 2011 income from operations of $899,000, income before income taxes of $822,000 and net income of $484,000, or $0.02 per share. The Company generated a 2012 year to date income from operations of $1,418,000, income before income taxes of $1,237,000 and net income of $793,000, or $0.03 per share, versus a 2011 year to date income from operations of $760,000, income before income taxes of $625,000 and net income of $374,000, or $0.01 per share.

Thomas Sandgaard, CEO stated: "We were pleased with our second quarter 2012 financial results, which were in line with our strong second quarter of the previous year. Our net revenue increased 19% and 26% during the three and six month periods of 2012, as compared to prior year, and increased 13% quarter over quarter, which is indicative of the demand for our Zynex Medical electrotherapy products and volume of orders our sales team continues to generate. Our Zynex Medical subsidiary still represents the majority of our revenue, but we are encouraged to see a contribution from our Zynex NeuroDiagnostics subsidiary, which includes the first quarter 2012 asset acquisition of NeuroDyne Medical. We continued to invest in our Zynex Medical and Zynex NeuroDiagnostics sales teams, through the addition of field sales representatives, which allowed us to expand our reach and penetration in key geographic markets. Our Zynex Monitoring Solutions subsidiary continues to make progress. We are currently participating in clinical trials expected to run through the remainder of 2012."

Outlook:
The Company confirms its initial guidance of anticipated total net revenue of between $38 million and $40 million for 2012 and net income per diluted share of between $0.06 and $0.08 for 2012.

Conference Call and Webcast Information:
Zynex, Inc. will host an earnings conference call and webcast at 9:00 a.m. MST (11:00 a.m. EST) today to discuss its second quarter 2012 financial results. Please note questions can only be submitted via the webcast user interface. Parties without access to the internet may join the presentation in listen only mode by dialing the toll free number provided below.

Webcast Information- http://www.visualwebcaster.com/event.asp?id=88637

Conference Call Information- 888-221-9541, pass-code 9400881

Highlights from the second quarter ended June 30, 2012 consolidated financial statements:
(unaudited, amounts in thousands, except per share amounts)

Three months ended Six months ended ----------------------- ----------------------- June 30, June 30, June 30, June 30, 2012 2011 2012 2011 ----------- ----------- ----------- ----------- Net revenue $ 10,026 $ 8,395 $ 18,970 $ 15,028 Gross profit 8,240 6,668 15,371 11,857 Income from operations 932 899 1,418 760 Income before income tax 844 822 1,237 625 Net income 473 484 793 374 Adjusted EBITDA (1) 1,151 1,148 1,833 1,253 Net income per share - diluted $ 0.02 $ 0.02 $ 0.03 $ 0.01 Weighted-average number of common shares outstanding -diluted 31,249,107 31,025,478 31,142,876 30,957,206

(1) Reconciliation of unaudited U.S. Generally Accepted Accounting Principles (GAAP) Net income (loss) to Adjusted Earnings Before Interest Taxes Depreciation, and Amortization (Adjusted-EBITDA)

Three months ended Six months ended -------------------- -------------------- June 30, June 30, June 30, June 30, 2012 2011 2012 2011 --------- --------- --------- --------- Net income $ 473 $ 484 $ 793 $ 374 Interest expense net and loss on extinguishment of debt 87 79 180 137 Income taxes 371 338 444 251 Depreciation and amortization 249 209 474 412 Deferred rent (73) (56) (148) (111) Stock-based expense 44 94 90 190 --------- --------- --------- --------- Adjusted EBITDA $ 1,151 $ 1,148 $ 1,833 $ 1,253 ========= ========= ========= =========

About Zynex

Zynex (founded in 1996), operates under three primary business segments; Zynex Medical, Zynex NeuroDiagnostics and Zynex Monitoring Solutions. Zynex Medical engineers, manufactures, markets and sells its own design of electrotherapy medical devices for electrotherapy, used for pain management and rehabilitation. Zynex Medical's product lines are fully developed, FDA-cleared and commercially sold world-wide. Zynex NeuroDiagnostics, sells the company's proprietary NeuroMove device designed to help stroke and spinal cord injury patients and is currently expanding into markets for EMG, EEG, sleep pattern, auditory and nerve conductivity neurological diagnosis devices through product development and acquisitions. Zynex Monitoring Solutions, currently in the development stage, has been established to develop and market medical devices for non-invasive cardiac monitoring.
For additional information, please visit: http://www.ir-site.com/zynex/default.asp.

Safe Harbor Statement

Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital in order to grow our business, our ability to engage additional sales representatives, the success of such additional sales representatives, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the uncertain outcome of pending material litigation and other risks described in our filings with the Securities and Exchange Commission including the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2011.

ZYNEX, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (AMOUNTS IN THOUSANDS, EXCEPT NUMBER OF SHARES) June 30, December 31, 2012 2011 ------------- ------------- (UNAUDITED) ASSETS Current Assets: Cash $ 623 $ 789 Accounts receivable, net 12,143 10,984 Inventory 6,554 4,556 Prepaid expenses 202 293 Deferred tax assets 1,469 1,384 Other current assets 44 42 ------------- ------------- Total current assets 21,035 18,048 Property and equipment, net 3,684 3,422 Deposits 168 170 Deferred financing fees, net 123 145 Intangible assets, net 233 - Goodwill 251 - ------------- ------------- Total assets $ 25,494 $ 21,785 ============= ============= LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Line of credit $ 5,201 $ 3,289 Current portion of notes payable and other obligations 139 131 Accounts payable 2,705 2,189 Income taxes payable 1,739 1,567 Accrued payroll and payroll taxes 980 702 Deferred rent 334 296 Current portion of contingent consideration 21 - Other accrued liabilities 1,376 1,574 ------------- ------------- Total current liabilities 12,495 9,748 Notes payable and other obligations, less current portion 187 258 Deferred rent 970 1,156 Deferred tax liabilities 511 483 Warranty liability 20 - Contingent consideration, less current portion 120 - ------------- ------------- Total liabilities 14,303 11,645 ------------- ------------- Stockholders' Equity: Preferred stock, $.001 par value, 10,000,000 shares authorized, no shares issued or outstanding - - Common stock, $.001 par value, 100,000,000 shares authorized, 31,108,109 and 30,816,631 shares issued and outstanding at June 30, 2012, and December 31, 2011, respectively. 31 31 Paid-in capital 5,354 5,096 Retained earnings 5,806 5,013 ------------- ------------- Total stockholders' equity 11,191 10,140 ------------- ------------- Total liabilities and stockholders' equity $ 25,494 $ 21,785 ============= ============= ZYNEX, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED, AMOUNTS IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA) Three Months Ended Six Months Ended June 30, June 30, ------------------------ ------------------------ 2012 2011 2012 2011 ----------- ----------- ----------- ----------- Net revenue: Rental $ 2,437 $ 2,447 $ 4,499 $ 4,895 Sales 7,589 5,948 14,471 10,133 ----------- ----------- ----------- ----------- 10,026 8,395 18,970 15,028 ----------- ----------- ----------- ----------- Cost of revenue: Rental 273 392 531 726 Sales 1,513 1,335 3,068 2,445 ----------- ----------- ----------- ----------- 1,786 1,727 3,599 3,171 ----------- ----------- ----------- ----------- Gross profit 8,240 6,668 15,371 11,857 Selling, general and administrative expense 7,308 5,769 13,953 11,097 ----------- ----------- ----------- ----------- Income from operations 932 899 1,418 760 ----------- ----------- ----------- ----------- Other income (expense): Interest income - 1 - 1 Interest expense (81) (80) (174) (138) Other income (expense) (7) 2 (7) 2 ----------- ----------- ----------- ----------- (88) (77) (181) (135) ----------- ----------- ----------- ----------- Income before income tax 844 822 1,237 625 Income tax expense 371 338 444 251 ----------- ----------- ----------- ----------- Net income $ 473 $ 484 $ 793 $ 374 =========== =========== =========== =========== Net income per share: Basic $ 0.02 $ 0.02 $ 0.03 $ 0.01 =========== =========== =========== =========== Diluted $ 0.02 $ 0.02 $ 0.03 $ 0.01 =========== =========== =========== =========== Weighted average number of common shares outstanding: Basic 31,091,900 30,756,717 30,986,478 30,694,216 =========== =========== =========== =========== Diluted 31,249,107 31,025,478 31,142,876 30,957,206 =========== =========== =========== =========== ZYNEX, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED, AMOUNTS IN THOUSANDS) Six Months Ended June 30, -------------------- 2012 2011 --------- --------- Cash flows from operating activities: Net income $ 793 $ 374 Adjustments to reconcile net income to net cash used in operating activities: Depreciation expense 432 389 Accretion of contingent consideration 6 - Provision for losses on uncollectible accounts receivable 158 630 Amortization of intangible assets 18 - Amortization of financing fees 24 23 Issuance of common stock for services - 44 Provision for obsolete inventory 190 - Deferred rent (148) (111) Employee stock-based compensation expense 90 146 Deferred tax benefit (57) (81) Changes in operating assets and liabilities net of business acquisition (Note 3): Accounts receivable (1,317) (2,834) Inventory (2,093) (93) Prepaid expenses 91 9 Deposit and other current assets 3 (49) Accounts payable 516 145 Accrued liabilities 80 609 Income taxes payable 172 (192) --------- --------- Net cash used in operating activities (1,042) (991) --------- --------- Cash flows from investing activities: Purchases of equipment and inventory used for rental (718) (739) Cash paid for domain name (18) - Cash paid for acquisition (245) - --------- --------- Net cash used in investing activities (981) (739) --------- --------- Cash flows from financing activities: Net borrowings from line of credit 1,912 1,934 Issuance of common stock 10 48 Deferred financing fees (2) (25) Payments on capital lease obligations (63) (46) --------- --------- Net cash provided by financing activities 1,857 1,911 --------- --------- Net increase in cash (166) 181 Cash at beginning of period 789 602 --------- --------- Cash at end of period $ 623 $ 783 ========= ========= Supplemental cash flow information: Interest paid $ 152 $ 102 Income taxes paid $ 365 $ 525 Supplemental disclosure of non-cash investing and financing activities: Common stock issuances for business acquisition $ 158 $ - Increase in contingent consideration for business acquisition $ 141 $ -


Contact:
Zynex, Inc.
Anthony Scalese
CFO
303-703-4906

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:


Read at BioSpace.com


comments powered by Disqus
Zynex
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES